Skip to main content
Top
Published in: BMC Medicine 1/2021

Open Access 01-12-2021 | Stroke | Research article

C2HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial

Authors: Weihao Liang, Yuzhong Wu, Ruicong Xue, Zexuan Wu, Dexi Wu, Jiangui He, Yugang Dong, Gregory Y. H. Lip, Wengen Zhu, Chen Liu

Published in: BMC Medicine | Issue 1/2021

Login to get access

Abstract

Background

The C2HEST score has been validated for predicting AF in the general population or post-stroke patients. We aimed to assess whether this risk score could predict incident AF and other clinical outcomes in heart failure with preserved ejection fraction (HFpEF) patients.

Methods

A total of 2202 HFpEF patients without baseline AF in the TOPCAT trial were stratified by baseline C2HEST score. Cox proportional hazard model and competing risk regression model was used to explore the relationship between C2HEST score and outcomes, including incident AF, stroke, all-cause death, cardiovascular death, any hospitalization, and HF hospitalization. The discriminative ability of the C2HEST score for various outcomes was assessed by calculating the area under the curve (AUC).

Results

The incidence rates of incident AF, stroke, all-cause death, cardiovascular death, any hospitalization, and HF hospitalization were 1.79, 0.70, 3.81, 2.42, 15.50, and 3.32 per 100 person-years, respectively. When the C2HEST score was analyzed as a continuous variable, increased C2HEST score was associated with increased risk of incident AF (HR 1.50, 95% CI 1.29–1.75), as well as increased risks of all-cause death, cardiovascular death, any hospitalization, and HF hospitalization. The AUC for the C2HEST score in predicting incident AF (0.694, 95% CI 0.640–0.748) was higher than all-cause death, cardiovascular death, any hospitalization, or HF hospitalization.

Conclusions

The C2HEST score could predict the risk of incident AF as well as death and hospitalization with moderately good predictive abilities in patients with HFpEF. Its simplicity may allow the possibility of quick risk assessments in busy clinical settings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Packer M, Lam C, Lund LH, Redfield MM. Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy. Circulation. 2020;141(1):4–6.PubMedCrossRef Packer M, Lam C, Lund LH, Redfield MM. Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy. Circulation. 2020;141(1):4–6.PubMedCrossRef
2.
go back to reference Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation. 2013;128(10):1085–93.PubMedPubMedCentralCrossRef Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation. 2013;128(10):1085–93.PubMedPubMedCentralCrossRef
3.
go back to reference Cikes M, Claggett B, Shah AM, Desai AS, Lewis EF, Shah SJ, Anand IS, O'Meara E, Rouleau JL, Sweitzer NK, et al. Atrial fibrillation in heart failure with preserved ejection fraction: the TOPCAT trial. JACC Heart Fail. 2018;6(8):689–97.PubMedCrossRef Cikes M, Claggett B, Shah AM, Desai AS, Lewis EF, Shah SJ, Anand IS, O'Meara E, Rouleau JL, Sweitzer NK, et al. Atrial fibrillation in heart failure with preserved ejection fraction: the TOPCAT trial. JACC Heart Fail. 2018;6(8):689–97.PubMedCrossRef
4.
go back to reference Abdul-Rahim AH, Perez AC, MacIsaac RL, Jhund PS, Claggett BL, Carson PE, Komajda M, McKelvie RS, Zile MR, Swedberg K, et al. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. Eur Heart J. 2017;38(10):742–50.PubMed Abdul-Rahim AH, Perez AC, MacIsaac RL, Jhund PS, Claggett BL, Carson PE, Komajda M, McKelvie RS, Zile MR, Swedberg K, et al. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. Eur Heart J. 2017;38(10):742–50.PubMed
5.
go back to reference Kasahara S, Sakata Y, Nochioka K, Tay WT, Claggett BL, Abe R, Oikawa T, Sato M, Aoyanagi H, Miura M, et al. The 3A3B score: the simple risk score for heart failure with preserved ejection fraction - a report from the CHART-2 study. Int J Cardiol. 2019;284:42–9.PubMedCrossRef Kasahara S, Sakata Y, Nochioka K, Tay WT, Claggett BL, Abe R, Oikawa T, Sato M, Aoyanagi H, Miura M, et al. The 3A3B score: the simple risk score for heart failure with preserved ejection fraction - a report from the CHART-2 study. Int J Cardiol. 2019;284:42–9.PubMedCrossRef
6.
go back to reference Himmelreich J, Veelers L, Lucassen W, Schnabel RB, Rienstra M, van Weert H, Harskamp RE. Prediction models for atrial fibrillation applicable in the community: a systematic review and meta-analysis. Europace. 2020:[Epub ahead of print]. Himmelreich J, Veelers L, Lucassen W, Schnabel RB, Rienstra M, van Weert H, Harskamp RE. Prediction models for atrial fibrillation applicable in the community: a systematic review and meta-analysis. Europace. 2020:[Epub ahead of print].
7.
go back to reference Li YG, Pastori D, Farcomeni A, Yang PS, Jang E, Joung B, Wang YT, Guo YT, Lip G. A simple clinical risk score (C2HEST) for predicting incident atrial fibrillation in Asian subjects: derivation in 471,446 Chinese subjects, with internal validation and external application in 451,199 Korean subjects. Chest. 2019;155(3):510–8.PubMedCrossRef Li YG, Pastori D, Farcomeni A, Yang PS, Jang E, Joung B, Wang YT, Guo YT, Lip G. A simple clinical risk score (C2HEST) for predicting incident atrial fibrillation in Asian subjects: derivation in 471,446 Chinese subjects, with internal validation and external application in 451,199 Korean subjects. Chest. 2019;155(3):510–8.PubMedCrossRef
8.
go back to reference Lip G, Skjoth F, Nielsen PB, Larsen TB. Evaluation of the C2HEST risk score as a possible opportunistic screening tool for incident atrial fibrillation in a healthy population (from a Nationwide Danish cohort study). Am J Cardiol. 2020;125(1):48–54.PubMedCrossRef Lip G, Skjoth F, Nielsen PB, Larsen TB. Evaluation of the C2HEST risk score as a possible opportunistic screening tool for incident atrial fibrillation in a healthy population (from a Nationwide Danish cohort study). Am J Cardiol. 2020;125(1):48–54.PubMedCrossRef
9.
go back to reference Li YG, Bisson A, Bodin A, Herbert J, Grammatico-Guillon L, Joung B, Wang YT, Lip G, Fauchier L. C2HEST score and prediction of incident atrial fibrillation in poststroke patients: a French Nationwide study. J Am Heart Assoc. 2019;8(13):e12546. Li YG, Bisson A, Bodin A, Herbert J, Grammatico-Guillon L, Joung B, Wang YT, Lip G, Fauchier L. C2HEST score and prediction of incident atrial fibrillation in poststroke patients: a French Nationwide study. J Am Heart Assoc. 2019;8(13):e12546.
10.
go back to reference Neefs J, van den Berg N, Krul S, Boekholdt SM, de Groot JR. Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. Am J Cardiovasc Drugs. 2020;20(1):73–80.PubMedCrossRef Neefs J, van den Berg N, Krul S, Boekholdt SM, de Groot JR. Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. Am J Cardiovasc Drugs. 2020;20(1):73–80.PubMedCrossRef
11.
go back to reference Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92.CrossRefPubMed Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92.CrossRefPubMed
12.
go back to reference Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507–15.PubMedCrossRef Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507–15.PubMedCrossRef
13.
go back to reference Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381–97.PubMedCrossRef Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381–97.PubMedCrossRef
14.
go back to reference Jolobe OM. Thyroid heart disease should include the coincidental association of hypothyroidism and atrial fibrillation. Am J Med. 2015;128(3):e9.PubMedCrossRef Jolobe OM. Thyroid heart disease should include the coincidental association of hypothyroidism and atrial fibrillation. Am J Med. 2015;128(3):e9.PubMedCrossRef
15.
go back to reference Bruere H, Fauchier L, Bernard BA, Pierre B, Simeon E, Babuty D, Clementy N. History of thyroid disorders in relation to clinical outcomes in atrial fibrillation. Am J Med. 2015;128(1):30–7.PubMedCrossRef Bruere H, Fauchier L, Bernard BA, Pierre B, Simeon E, Babuty D, Clementy N. History of thyroid disorders in relation to clinical outcomes in atrial fibrillation. Am J Med. 2015;128(1):30–7.PubMedCrossRef
16.
go back to reference Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34–42.PubMedCrossRef Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34–42.PubMedCrossRef
17.
go back to reference Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107(23):2920–5.PubMedCrossRef Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107(23):2920–5.PubMedCrossRef
18.
go back to reference Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation. 2015;131(25):2176–84.PubMedCrossRef Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation. 2015;131(25):2176–84.PubMedCrossRef
19.
go back to reference Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, Oh JK, Leibson C, Montgomery SC, Seward JB. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40(9):1636–44.PubMedCrossRef Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, Oh JK, Leibson C, Montgomery SC, Seward JB. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40(9):1636–44.PubMedCrossRef
20.
go back to reference Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Iles R, Lip GY, Davies MK. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace. 2012;14(11):1553–9.PubMedCrossRef Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Iles R, Lip GY, Davies MK. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace. 2012;14(11):1553–9.PubMedCrossRef
21.
go back to reference Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.PubMedCrossRef Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.PubMedCrossRef
22.
go back to reference Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JJ, Kemper AR, Kubik M, et al. Screening for atrial fibrillation with electrocardiography: US preventive services task force recommendation statement. JAMA. 2018;320(5):478–84.PubMedCrossRef Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JJ, Kemper AR, Kubik M, et al. Screening for atrial fibrillation with electrocardiography: US preventive services task force recommendation statement. JAMA. 2018;320(5):478–84.PubMedCrossRef
23.
go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland J, Coats A, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.PubMedCrossRef Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland J, Coats A, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.PubMedCrossRef
24.
go back to reference Apostolakis S, Sullivan RM, Olshansky B, Lip G. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest. 2013;144(5):1555–63.PubMedCrossRef Apostolakis S, Sullivan RM, Olshansky B, Lip G. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest. 2013;144(5):1555–63.PubMedCrossRef
25.
go back to reference Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RS, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009;373(9665):739–45.PubMedPubMedCentralCrossRef Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RS, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009;373(9665):739–45.PubMedPubMedCentralCrossRef
26.
go back to reference Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R, Ambrose M, Alonso A. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011;107(1):85–91.PubMedPubMedCentralCrossRef Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R, Ambrose M, Alonso A. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011;107(1):85–91.PubMedPubMedCentralCrossRef
27.
go back to reference Suenari K, Chao TF, Liu CJ, Kihara Y, Chen TJ, Chen SA. Usefulness of HATCH score in the prediction of new-onset atrial fibrillation for Asians. Medicine (Baltimore). 2017;96(1):e5597.CrossRef Suenari K, Chao TF, Liu CJ, Kihara Y, Chen TJ, Chen SA. Usefulness of HATCH score in the prediction of new-onset atrial fibrillation for Asians. Medicine (Baltimore). 2017;96(1):e5597.CrossRef
28.
go back to reference Pfister R, Bragelmann J, Michels G, Wareham NJ, Luben R, Khaw KT. Performance of the CHARGE-AF risk model for incident atrial fibrillation in the EPIC Norfolk cohort. Eur J Prev Cardiol. 2015;22(7):932–9.PubMedCrossRef Pfister R, Bragelmann J, Michels G, Wareham NJ, Luben R, Khaw KT. Performance of the CHARGE-AF risk model for incident atrial fibrillation in the EPIC Norfolk cohort. Eur J Prev Cardiol. 2015;22(7):932–9.PubMedCrossRef
29.
go back to reference Saliba W, Gronich N, Barnett-Griness O, Rennert G. Usefulness of CHADS2 and CHA2DS2-VASc scores in the prediction of new-onset atrial fibrillation: a population-based study. Am J Med. 2016;129(8):843–9.PubMedCrossRef Saliba W, Gronich N, Barnett-Griness O, Rennert G. Usefulness of CHADS2 and CHA2DS2-VASc scores in the prediction of new-onset atrial fibrillation: a population-based study. Am J Med. 2016;129(8):843–9.PubMedCrossRef
30.
go back to reference Kokubo Y, Watanabe M, Higashiyama A, Nakao YM, Kusano K, Miyamoto Y. Development of a basic risk score for incident atrial fibrillation in a Japanese general population- the Suita study. Circ J. 2017;81(11):1580–8.PubMedCrossRef Kokubo Y, Watanabe M, Higashiyama A, Nakao YM, Kusano K, Miyamoto Y. Development of a basic risk score for incident atrial fibrillation in a Japanese general population- the Suita study. Circ J. 2017;81(11):1580–8.PubMedCrossRef
31.
go back to reference Nielsen JC, Lin YJ, de Oliveira FM, Sepehri SA, Alfie A, Boveda S, Dagres N, Di Toro D, Eckhardt LL, Ellenbogen K, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. J Arrhythm. 2020;36(4):553–607.PubMedPubMedCentralCrossRef Nielsen JC, Lin YJ, de Oliveira FM, Sepehri SA, Alfie A, Boveda S, Dagres N, Di Toro D, Eckhardt LL, Ellenbogen K, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. J Arrhythm. 2020;36(4):553–607.PubMedPubMedCentralCrossRef
32.
go back to reference Everett BM, Cook NR, Conen D, Chasman DI, Ridker PM, Albert CM. Novel genetic markers improve measures of atrial fibrillation risk prediction. Eur Heart J. 2013;34(29):2243–51.PubMedPubMedCentralCrossRef Everett BM, Cook NR, Conen D, Chasman DI, Ridker PM, Albert CM. Novel genetic markers improve measures of atrial fibrillation risk prediction. Eur Heart J. 2013;34(29):2243–51.PubMedPubMedCentralCrossRef
33.
go back to reference Okubo Y, Nakano Y, Ochi H, Onohara Y, Tokuyama T, Motoda C, Amioka M, Hironobe N, Okamura S, Ikeuchi Y et al. Predicting atrial fibrillation using a combination of genetic risk score and clinical risk factors. Heart Rhythm. 2020:[Epub ahead of print]. Okubo Y, Nakano Y, Ochi H, Onohara Y, Tokuyama T, Motoda C, Amioka M, Hironobe N, Okamura S, Ikeuchi Y et al. Predicting atrial fibrillation using a combination of genetic risk score and clinical risk factors. Heart Rhythm. 2020:[Epub ahead of print].
34.
go back to reference Hu WS, Hsieh MH, Lin CL. A novel atrial fibrillation prediction model for Chinese subjects: a nationwide cohort investigation of 682 237 study participants with random forest model. Europace. 2019;21(9):1307–12.PubMedCrossRef Hu WS, Hsieh MH, Lin CL. A novel atrial fibrillation prediction model for Chinese subjects: a nationwide cohort investigation of 682 237 study participants with random forest model. Europace. 2019;21(9):1307–12.PubMedCrossRef
35.
go back to reference Baumgartner C, Da CB, Collet TH, Feller M, Floriani C, Bauer DC, Cappola AR, Heckbert SR, Ceresini G, Gussekloo J, et al. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation. 2017;136(22):2100–16.PubMedPubMedCentralCrossRef Baumgartner C, Da CB, Collet TH, Feller M, Floriani C, Bauer DC, Cappola AR, Heckbert SR, Ceresini G, Gussekloo J, et al. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation. 2017;136(22):2100–16.PubMedPubMedCentralCrossRef
36.
go back to reference Ellervik C, Roselli C, Christophersen IE, Alonso A, Pietzner M, Sitlani CM, Trompet S, Arking DE, Geelhoed B, Guo X, et al. Assessment of the relationship between genetic determinants of thyroid function and atrial fibrillation: a Mendelian randomization study. JAMA Cardiol. 2019;4(2):144–52.PubMedPubMedCentralCrossRef Ellervik C, Roselli C, Christophersen IE, Alonso A, Pietzner M, Sitlani CM, Trompet S, Arking DE, Geelhoed B, Guo X, et al. Assessment of the relationship between genetic determinants of thyroid function and atrial fibrillation: a Mendelian randomization study. JAMA Cardiol. 2019;4(2):144–52.PubMedPubMedCentralCrossRef
37.
go back to reference Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J. 2007;28(22):2803–17.PubMedCrossRef Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J. 2007;28(22):2803–17.PubMedCrossRef
38.
go back to reference Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, Balasubramanian V, Russo AM, Rajmane A, Cheung L, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381(20):1909–17.PubMedCrossRefPubMedCentral Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, Balasubramanian V, Russo AM, Rajmane A, Cheung L, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381(20):1909–17.PubMedCrossRefPubMedCentral
39.
go back to reference Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, Yan L, Xing Y, Shi H, Li S, et al. Mobile photoplethysmographic technology to detect atrial fibrillation. J Am Coll Cardiol. 2019;74(19):2365–75.PubMedCrossRef Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, Yan L, Xing Y, Shi H, Li S, et al. Mobile photoplethysmographic technology to detect atrial fibrillation. J Am Coll Cardiol. 2019;74(19):2365–75.PubMedCrossRef
40.
go back to reference Tsang TS, Barnes ME, Pellikka PA, Gin K, Miyasaka Y, Seward JB, Gersh BJ. 173 Silent atrial fibrillation in olmsted county: a community-based study. Can J Cardiol. 2011;27(5):S122.CrossRef Tsang TS, Barnes ME, Pellikka PA, Gin K, Miyasaka Y, Seward JB, Gersh BJ. 173 Silent atrial fibrillation in olmsted county: a community-based study. Can J Cardiol. 2011;27(5):S122.CrossRef
41.
go back to reference Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. Thromb Haemost. 2014;112(2):276–86.PubMedPubMedCentralCrossRef Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. Thromb Haemost. 2014;112(2):276–86.PubMedPubMedCentralCrossRef
42.
go back to reference Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;151(5):985–91.PubMedCrossRef Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;151(5):985–91.PubMedCrossRef
43.
go back to reference Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55(21):2299–307.PubMedCrossRef Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55(21):2299–307.PubMedCrossRef
44.
go back to reference Zhu W, Wu Y, Zhou Y, Liang W, Xue R, Wu Z, Dong Y, Liu C. CHA2DS2-VASc and ATRIA scores and clinical outcomes in patients with heart failure with preserved ejection fraction. Cardiovasc Drugs Ther. 2020;34(6):763-72. Zhu W, Wu Y, Zhou Y, Liang W, Xue R, Wu Z, Dong Y, Liu C. CHA2DS2-VASc and ATRIA scores and clinical outcomes in patients with heart failure with preserved ejection fraction. Cardiovasc Drugs Ther. 2020;34(6):763-72.
Metadata
Title
C2HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial
Authors
Weihao Liang
Yuzhong Wu
Ruicong Xue
Zexuan Wu
Dexi Wu
Jiangui He
Yugang Dong
Gregory Y. H. Lip
Wengen Zhu
Chen Liu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2021
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-021-01921-w

Other articles of this Issue 1/2021

BMC Medicine 1/2021 Go to the issue